Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

This study supports the addition of MDT to systemic therapy for patients with oligometastatic PDAC. Induction of systemic immunity is a possible mechanism of benefit. These results warrant confirmatory trials to refine treatment strategy and provide external validation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-08-05
DOI
https://doi.org/10.1200/jco.24.00081
Citations
49
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
13.84

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

Rachael Martin, L Perles, Matthew H. G. Katz, Emma B. Holliday et al.
49 citations
Journal of Clinical Oncology
Pancreatic and Hepatic Oncology Research
13.84
article

Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial

Rachael Martin, L Perles, Matthew H. G. Katz, Emma B. Holliday, T R Price, Chad Z. Tang, Alexander D. Sherry, Dan Zhao, Brandon G. Smaglo, Ethan B. Ludmir, Eugene J. Koay, Lorenzo Cohen, Suyu Liu, Robert A. Wolff, Sonal S. Noticewala, Cara Haymaker, Sunyoung S. Lee, Grace L. Smith, Ryan W. Huey, Jason A. Willis, Marina Nayeli Medina-Rosales, Albert C. Koong, Cullen M. Taniguchi, Bryan Fellman, Tharakeswara Bathala, Prajnan Das, Shubham Pant, Michael S. Lee, Alexandre Reuben, Sarah Nicholas
article en
49 citations

Abstract

This study supports the addition of MDT to systemic therapy for patients with oligometastatic PDAC. Induction of systemic immunity is a possible mechanism of benefit. These results warrant confirmatory trials to refine treatment strategy and provide external validation.

Journal of Clinical OncologyVol. 42(32)
The University of Texas MD Anderson Cancer Center (US), Community Health Network (US), Banner MD Anderson Cancer Center
Cancer Prevention and Research Institute of Texas, University of Texas MD Anderson Cancer Center, National Cancer Institute
Good health and well-being
Openalex Percentile: Top 1%
Pancreatic and Hepatic Oncology Research
13.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.